• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Tuberculosis - Pipeline Review, H2 2013 - Product Image

Tuberculosis - Pipeline Review, H2 2013

  • Published: August 2013
  • 259 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Archivel Farma S.L.
  • BT PHARMA
  • Ensoltek Co., Ltd.
  • ImmunoBiology Limited
  • Mondobiotech Holding AG
  • Pt. Bio Farma
  • MORE

Tuberculosis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tuberculosis. Tuberculosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Tuberculosis.
- A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Tuberculosis Overview
Therapeutics Development
An Overview of Pipeline Products for Tuberculosis
Tuberculosis Therapeutics under Development by Companies
Tuberculosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Tuberculosis Therapeutics - Products under Development by Companies
Tuberculosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Tuberculosis Therapeutics Development
Johnson & Johnson
Sequella, Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Piramal Healthcare Limited
Achillion Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated
AVI BioPharma Inc.
Crucell N.V.
Hollis-Eden Pharmaceuticals, Inc.
Transgene SA
Summit Corporation plc
Immune Network Research Ltd.
Advinus Therapeutics Pvt. Ltd.
Snowdon Inc.
Statens Serum Institut
ImmunoBiology Limited
Recipharm AB
Pt. Bio Farma
MicuRx Pharmaceuticals, Inc.
Mondobiotech Holding AG
Okairos
EpiVax, Inc.
Archivel Farma S.L.
Chimerix, Inc.
Pharminox Limited
ImmunoVaccine Technologies Inc.
BT PHARMA
Canopus BioPharma Incorporated
TVAX Biomedical, LLC
Medisyn Technologies, Inc.
Vakzine Projekt Management GmbH
Ensoltek Co., Ltd.
B&C Biopharm
GlaxoSmithKline Inc.
NeED Pharma s.r.l.
Vichem Chemie Research Ltd.
ISA Pharmaceuticals B.V.
Lipotek Pty Ltd
Tuberculosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
delamanid - Drug Profile
delamanid - Drug Profile
SND-159 - Drug Profile
bedaquiline fumarate - Drug Profile
SQ-109 - Drug Profile
Tuberculosis Vaccine - Drug Profile
rifalazil - Drug Profile
SQ-609 - Drug Profile
NasL3/HtkBCG Vaccine - Drug Profile
MTBVAC01 - Drug Profile
sutezolid - Drug Profile
VPM-1002 - Drug Profile
HG-85A/B - Drug Profile
HG856-A - Drug Profile
HG856-BCG - Drug Profile
PS-Conjugate Vaccine - Drug Profile
GSK-692342 - Drug Profile
R32Kda-BCG Vaccine - Drug Profile
r30 Vaccine - Drug Profile
TB Proteasome Inhibitors - Drug Profile
AERAS-Capsid Vaccine - Drug Profile
HBHA Vaccine - Drug Profile
Streptomyces Live Vector Vaccine - Drug Profile
rBCG(mbtB)30 Vaccine - Drug Profile
Drug For Tuberculosis - Drug Profile
Crucell Ad-35 - Drug Profile
RUTI Vaccine - Drug Profile
AZD-5847 - Drug Profile
PA-824 - Drug Profile
Vaccine For Tuberculosis - Drug Profile
HE-2000 - Drug Profile
V-5 - Drug Profile
NasL3/AM85B Vaccine - Drug Profile
Mycobacterial Liposomes And Proteosomal Vaccine - Drug Profile
paBCG Vaccine - Drug Profile
AERAS-422 Vaccine - Drug Profile
Drug For Tuberculosis - Drug Profile
FP6 TBVAC - Drug Profile
ORT-VAC DNA Vaccine - Drug Profile
IMX-313-TB - Drug Profile
DasKloster-024901 - Drug Profile
Anti-Bacterial Program - Drug Profile
TB-SLP - Drug Profile
Drug For Tuberculosis - Drug Profile
Bacterial PPMO - Drug Profile
MTbuVax - Drug Profile
SSI H56-IC31 - Drug Profile
MicroRNA-Like Molecules - Drug Profile
PMX-464 - Drug Profile
TVI-Tuberculosis-1 - Drug Profile
T-Biovax - Drug Profile
PM-181108 - Drug Profile
Tuberculosis Program - Drug Profile
V-7 Vaccine - Drug Profile
Multi-Epitope Tuberculosis Vaccine - Drug Profile
Mtb Vaccine - Drug Profile
HG-85A - Drug Profile
TB Vaccine - Drug Profile
LIP1 Ac2SGL Sulfoglycolipid - Drug Profile
Latency Fusion Proteins Based Vaccine - Drug Profile
Recombinant LCMV Vaccine - Drug Profile
pUMVC6/7 DNA Vaccine - Drug Profile
IKEPLUS - Drug Profile
DNAacr Vaccine - Drug Profile
LIP2 SL37 (synthetic) Sulfoglycolipid Vaccine - Drug Profile
S006-830 - Drug Profile
TBA-354 - Drug Profile
TB Therapeutic Vaccine - Drug Profile
Drug For Tuberculosis - Drug Profile
3-(4-chlorophenyl)-4-Substituted Pyrazole Derivatives - Drug Profile
Anti-Tuberculosis Program - Drug Profile
mepenzolate bromide - Drug Profile
CPZEN-45 - Drug Profile
ND-801 - Drug Profile
ND-701 - Drug Profile
ND-201 - Drug Profile
ND-601 - Drug Profile
InhA inhibitors - Drug Profile
TB-10.4 - Drug Profile
VI-15910 - Drug Profile
BT Compound Systemic - Drug Profile
BT Compound Inhalation - Drug Profile
Enoyl Reductase Inhibitors - Drug Profile
ebselen - Drug Profile
methionine sulfoximine - Drug Profile
rBCG30 Vaccine - Drug Profile
Live Recombinant Booster Vaccine - Drug Profile
Tuberculosis Vaccine - Drug Profile
NM-031 - Drug Profile
MDR And XDR Tuberculosis Program - Drug Profile
ADX40-TB - Drug Profile
Drug For Infectious Diseases - Drug Profile
RNA Polymerase Inhibitors - Drug Profile
Tuberculosis Vaccine - Drug Profile
Compound-6 For Tuberculosis - Drug Profile
Compound-5 For Tuberculosis - Drug Profile
VI-18469 - Drug Profile
VI-9376 - Drug Profile
AX-20017 - Drug Profile
VI-14585 - Drug Profile
VI-15843 - Drug Profile
Neglected Disease Program 1 - Drug Profile
Neglected Disease Program 2 - Drug Profile
Q-203 - Drug Profile
Sharon-1000 - Drug Profile
Tuberculosis Vaccine - Drug Profile
MGyrX1 Inhibitor - Drug Profile
BTZ-043 - Drug Profile
Vaccine For Tuberculosis - Drug Profile
Ad5Ag85A Vaccine - Drug Profile
Anti-Connection Drug - Drug Profile
Drug For Tuberculosis - Drug Profile
Pantothenate Synthetase Inhibitor - Drug Profile
Tuberculosis Vaccine Program - Drug Profile
Tuberculosis Project - Drug Profile
Pam2Cys Vaccine - Drug Profile
Diarylquinoline - Drug Profile
TCA1 - Drug Profile
Pyrazinamide Analogs - Drug Profile
DprE Inhibitors - Drug Profile
Tuberculosis Program - Drug Profile
Macrolides - Drug Profile
Cyclopeptides - Drug Profile
RNA Polymerase Inhibitors - Drug Profile
S-008-1167 - Drug Profile
S-008-1635 - Drug Profile
S-008-895 - Drug Profile
S-008-0399 - Drug Profile
Compound-8a - Drug Profile
Compound-12 - Drug Profile
Compound-13 - Drug Profile
Compound-6a - Drug Profile
Tuberculosis Therapeutics - Drug Profile Updates
Tuberculosis Therapeutics - Discontinued Products
Tuberculosis Therapeutics - Dormant Products
Tuberculosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Tuberculosis, H2 2013
Products under Development for Tuberculosis - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Development by Companies, H2 2013 (Contd..1)
Number of Products under Development by Companies, H2 2013 (Contd..2)
Number of Products under Development by Companies, H2 2013 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Development by Companies, H2 2013 (Contd..1)
Products under Development by Companies, H2 2013 (Contd..2)
Products under Development by Companies, H2 2013 (Contd..3)
Products under Development by Companies, H2 2013 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2013
Products under Investigation by Universities/Institutes, H2 2013 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2013 (Contd..2)
Johnson & Johnson, H2 2013
Sequella, Inc., H2 2013
Sanofi-Aventis, H2 2013
AstraZeneca PLC, H2 2013
Eli Lilly and Company, H2 2013
GlaxoSmithKline plc, H2 2013
Piramal Healthcare Limited, H2 2013
Achillion Pharmaceuticals, Inc., H2 2013
Vertex Pharmaceuticals Incorporated, H2 2013
AVI BioPharma Inc., H2 2013
Crucell N.V., H2 2013
Hollis-Eden Pharmaceuticals, Inc., H2 2013
Transgene SA, H2 2013
Summit Corporation plc, H2 2013
Immune Network Research Ltd., H2 2013
Advinus Therapeutics Pvt. Ltd., H2 2013
Snowdon Inc., H2 2013
Statens Serum Institut, H2 2013
ImmunoBiology Limited, H2 2013
Recipharm AB, H2 2013
Pt. Bio Farma, H2 2013
MicuRx Pharmaceuticals, Inc., H2 2013
Mondobiotech Holding AG, H2 2013
Okairos, H2 2013
EpiVax, Inc., H2 2013
Archivel Farma S.L., H2 2013
Chimerix, Inc., H2 2013
Pharminox Limited, H2 2013
ImmunoVaccine Technologies Inc., H2 2013
BT PHARMA, H2 2013
Canopus BioPharma Incorporated, H2 2013
TVAX Biomedical, LLC, H2 2013
Medisyn Technologies, Inc., H2 2013
Vakzine Projekt Management GmbH, H2 2013
Ensoltek Co., Ltd., H2 2013
B&C Biopharm, H2 2013
GlaxoSmithKline Inc., H2 2013
NeED Pharma s.r.l., H2 2013
Vichem Chemie Research Ltd., H2 2013
ISA Pharmaceuticals B.V., H2 2013
Lipotek Pty Ltd, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Tuberculosis Therapeutics - Drug Profile Updates
Tuberculosis Therapeutics - Discontinued Products
Tuberculosis Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Tuberculosis, H2 2013
Products under Development for Tuberculosis - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 88

Johnson & Johnson
Sequella, Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Piramal Healthcare Limited
Achillion Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated
AVI BioPharma Inc.
Crucell N.V.
Hollis-Eden Pharmaceuticals, Inc.
Transgene SA
Summit Corporation plc
Immune Network Research Ltd.
Advinus Therapeutics Pvt. Ltd.
Snowdon Inc.
Statens Serum Institut
ImmunoBiology Limited
Recipharm AB
Pt. Bio Farma
MicuRx Pharmaceuticals, Inc.
Mondobiotech Holding AG
Okairos
EpiVax, Inc.
Archivel Farma S.L.
Chimerix, Inc.
Pharminox Limited
ImmunoVaccine Technologies Inc.
BT PHARMA
Canopus BioPharma Incorporated
TVAX Biomedical, LLC
Medisyn Technologies, Inc.
Vakzine Projekt Management GmbH
Ensoltek Co., Ltd.
B&C Biopharm
GlaxoSmithKline Inc.
NeED Pharma s.r.l.
Vichem Chemie Research Ltd.
ISA Pharmaceuticals B.V.
Lipotek Pty Ltd

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos